Novel BBB disrupting platform with chemoimmunotherapy against glioma

Description:

This in-vivo study explores the use of a newly developed chemical entity as a possible BBB disrupting agent that will be administrated together with chemoimmunothrapy to improve drug delivery and treatment for glioma.

Contact Person:

Dr. Itzik Cooper

PI: Dr. Itzik Cooper, Prof. Yael Mardor

Funding:

Israel Innovation Authority (Kamin)

Collaborations - local and global:

Prof. Yael Mardor (The Advanced Technology Center, Sheba)